The microglial neuroimmune axis represents a critical but underappreciated component of Corticobasal Syndrome (CBS) pathophysiology. While 4R-tauopathies like CBS and Progressive Supranuclear Palsy (PSP) are primarily defined by their tau pathology, accumulating evidence demonstrates that microglia—the resident immune cells of the central nervous system—play a pivotal role in disease progression, propagation of pathology, and therapeutic response. Single-cell transcriptomics studies from 2023-2024 have revealed disease-specific microglial states that differ markedly between CBS and other neurodegenerative conditions[1][2].
Microglia in CBS exist in a complex and dynamic state, shaped by interactions with tau protein aggregates, TDP-43 pathology, neuronal damage signals, and the broader neuroimmune environment. Understanding this microglial landscape is essential for developing disease-modifying therapies that target neuroinflammation rather than merely addressing protein pathology.
Microglia arise from yolk-sac progenitors during embryonic development and seed the developing brain before the establishment of the blood-brain barrier. Unlike peripheral macrophages, microglia are self-renewing through local proliferation, with minimal contribution from bone-marrow-derived cells in the healthy adult brain[3]. This tissue-resident nature means that microglial populations in CBS have been present since early development, undergoing decades of interaction with the brain parenchyma before disease onset.
In the normal brain, microglia perform essential homeostatic functions:
The microglial response in CBS is shaped by several key receptor systems:
| Receptor | Ligand/Trigger | Function in CBS |
|---|---|---|
| TREM2 | Lipids, APOE, PSAP | Phagocytosis, survival signaling, DAM transition[5] |
| P2Y12 | ADP/ATP | Process extension, synaptic surveillance[4:1] |
| CX3CR1 | CX3CL1 (fractalkine) | Neuron-microglia crosstalk, anti-inflammatory tone |
| TLR4 | DAMPs, misfolded proteins | Pro-inflammatory activation |
| CSF1R | IL-34, CSF-1 | Survival, proliferation |
| NLRP3 | Tau aggregates, ATP | Inflammasome activation, IL-1beta release |
A landmark framework from Keren-Shaul et al. described a continuum of microglial activation states in neurodegenerative disease[6]. The neurodegenerative-associated microglia (DAM) program represents a protective response characterized by:
In CBS, the DAM program shows distinctive features that differ from Alzheimer's Disease (AD) and Parkinson's Disease[7]:
Single-cell RNA sequencing studies in CBS and PSP have revealed at least five distinct microglial states[2:1][1:1]:
| Microglial State | Frequency in CBS | Key Markers | Functional Profile |
|---|---|---|---|
| Homeostatic (HM) | 20-30% | CX3CR1+, P2Y12+, Tmem119+ | Surveillance, low inflammation |
| DAM-1 (transition) | 15-20% | TREM2+, Apoe+ | Early response to pathology |
| DAM-2 (full) | 25-35% | Lpl+, Ctsd+, Itgax+ | Phagocytosis, lipid metabolism |
| Inflammatory (IM) | 10-15% | IL1B+, TNF+, CCL2+ | Pro-inflammatory, neurotoxic |
| Senescent (SAM) | 5-10% | p21+, p16+, SA-beta-gal+ | Irreversible growth arrest |
The distribution of microglial states in CBS follows the characteristic asymmetric pattern of the disease[1:2]:
Triggering receptor expressed on myeloid cells 2 (TREM2) is a surface receptor predominantly expressed on microglia and macrophages. TREM2 signaling promotes microglial survival, enhances phagocytosis of apoptotic cells and protein aggregates, and drives the transition to the DAM program[5:1].
TREM2 ligands include:
Common and rare TREM2 variants influence CBS susceptibility and microglial function[8:1]:
The impact of TREM2 variants on CBS differs from AD: in AD, R47H dramatically increases risk (~3-4x), whereas in CBS the effect is more modest (~1.5-2x), suggesting that 4R-tau pathology can engage microglial responses even without full TREM2 signaling[8:2].
TREM2 represents a promising therapeutic target for CBS[10]:
Microglia actively phagocytose extracellular and cell-associated tau species. However, this process is often ineffective in 4R-tauopathies, leading to a cycle of uptake, incomplete degradation, and re-release of tau fragments[11][12]:
Tau aggregates directly activate microglia through multiple pathways[11:1]:
A key paradox in CBS is that despite high microglial activation, tau pathology continues to propagate. Potential explanations include:
While the primary focus of CBS microglia research has been on tau pathology, a significant subset of CBS cases (~30-40%) also feature TDP-43 pathology[@murakami2025]. Microglial interactions with TDP-43 show distinctive features[14]:
CBS patients show elevated cerebrospinal fluid (CSF) and plasma levels of several pro-inflammatory cytokines[15]:
| Cytokine | Change in CBS | Source | Functional Impact |
|---|---|---|---|
| IL-1β | ↑ 2-3x vs controls | Microglia, infiltrating macrophages | Drives neuroinflammation, tau phosphorylation |
| TNF-α | ↑ 1.5-2x | Activated microglia | Promotes neuronal apoptosis, complements cascade |
| IL-6 | ↑ 2-4x | Glial cells, endothelial cells | Chronic inflammation, HPA axis activation |
| CXCL8 (IL-8) | ↑ 1.5-2x | Microglia, astrocytes | Neutrophil recruitment, blood-brain barrier disruption |
| IFN-γ | ↑ 1.5x | T cells (if CNS-infiltrating) | Synergizes with TNF-α for neurotoxicity |
Counter-regulatory cytokines modulate the inflammatory response in CBS:
The complement system is strongly activated in CBS, particularly the classical pathway[13:1]:
Complement activation in CBS drives both synaptic loss (through C1q-mediated tagging of synapses for microglial phagocytosis) and tau propagation (through C3-fragment deposition that facilitates protein aggregate uptake).
Translocator protein (TSPO) is a mitochondrial receptor highly expressed in activated microglia. TSPO PET imaging enables in vivo quantification of neuroinflammation[17][18]:
TSPO PET studies in CBS reveal characteristic patterns[17:1][18:1]:
| Disease | TSPO Pattern | Regional Intensity |
|---|---|---|
| CBS | Asymmetric, cortical + subcortical | Putamen > motor cortex > brainstem |
| PSP | Symmetric, predominantly subcortical | Globus pallidus > brainstem > cortical |
| AD | Symmetric, predominantly cortical | Prefrontal cortex > posterior cingulate |
Microglia maintain synaptic homeostasis through activity-dependent pruning of synapses, primarily mediated by:
In CBS, microglial synaptic pruning becomes dysregulated, contributing to early synaptic loss[17:2]:
A subset of CBS microglia adopt a senescence-associated phenotype that contributes to chronic neuroinflammation and impaired tissue repair[9:1]:
Several microglial-targeting strategies are in clinical development or recently completed trials[10:1]:
| Target | Agent | Stage | Mechanism |
|---|---|---|---|
| TREM2 | AL002 (AbbVie/Alector) | Phase 2 (AD, ALS) | Agonist antibody |
| CSF1R | PLX3397 (pexidartinib) | Phase 1 (PSP) | Kinase inhibitor |
| NLRP3 | MCC950 | Preclinical | Inflammasome inhibitor |
| P2Y12 | Ticagrelor | Phase 2 (stroke) | P2Y12 antagonist |
| TSPO | Ethylene-014 | Preclinical | TSPO antagonist |
Several approved drugs have microglial effects relevant to CBS:
Microglia and astrocytes form a tightly coupled neuroimmune unit. In CBS, microglial activation drives astrocyte reactivity through secreted cytokines[19]:
This creates a self-reinforcing neuroinflammatory loop: tau pathology activates microglia → microglia induce A1 astrocytes → A1 astrocytes damage neurons → neuronal damage further activates microglia.
Miron J et al. Single-cell RNA-seq of microglia in corticobasal degeneration. Nat Neurosci. 2023. ↩︎ ↩︎ ↩︎
Hopp K et al. Microglial phenotypes in CBS and PSP based on single-cell analysis. Acta Neuropathol Commun. 2024. ↩︎ ↩︎
Kettenmann H et al. Physiology of microglia. Physiol Rev. 2011. ↩︎
Razgondejad-Abad S et al. P2Y12 receptor-dependent microglial process extension in CBS. Glia. 2024. ↩︎ ↩︎ ↩︎
Johnson NR et al. TREM2-dependent microglial states in neurodegenerative disease. Nat Rev Neurol. 2022. ↩︎ ↩︎
Keren-Shaul H et al. A unique microglia type associated with restricting Alzheimer's disease. Cell. 2017. ↩︎
Rothenberger F et al. Neurodegeneration-associated microglia (DAM) in corticobasal syndrome. Acta Neuropathol Commun. 2022. ↩︎
Yang J et al. TREM2 genetic variants influence CBS susceptibility and inflammation. Acta Neuropathol. 2024. ↩︎ ↩︎ ↩︎
Yerbury JJ et al. The intersection of microglial senescence and tau pathology in 4R-tauopathies. Front Aging Neurosci. 2017. ↩︎ ↩︎
Kim JS et al. Pharmacological targeting of microglia in CBS via TREM2 modulation. Neurobiol Dis. 2023. ↩︎ ↩︎
Depboylu C et al. Phosphorylation of tau protein in proximity to microglia in corticobasal degeneration. Brain Pathol. 2012. ↩︎ ↩︎
Escott C et al. Microglial states and tau pathology interactions in 4R-tauopathies. Glia. 2021. ↩︎
Confavreux CC et al. Complement cascade activation in CBS and relationship to tau burden. J Neuroinflammation. 2022. ↩︎ ↩︎
Zhao Y et al. TDP-43 pathophysiology in microglia and therapeutic implications. Trends Neurosci. 2022. ↩︎
Sanchez-Guajardo V et al. Microglial alterations in corticobasal degeneration. J Neuroinflammation. 2015. ↩︎
Boche D et al. Transforming growth factor beta in CNS disease and the microglial response. Trends Neurosci. 2021. ↩︎
Malpetti M et al. Microglial activity and synaptic loss in corticobasal syndrome. Brain. 2020. ↩︎ ↩︎ ↩︎
Tang Y et al. TSPO PET longitudinal changes in CBS progression. Neuroimage Clin. 2025. ↩︎ ↩︎ ↩︎
Liddelow SA et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017. ↩︎